115 results
Page 4 of 6
8-K
EX-99.1
89tbvyfv3j 8ky4lvm
31 Mar 21
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal
7:32am
8-K
EX-99.1
mxmj7
1 Mar 21
Zai Lab Announces Financial Results
7:01am
10-K
EX-10.21
0q3z06y
1 Mar 21
Annual report
12:00am
10-K
EX-10.20
p6m ajryg
1 Mar 21
Annual report
12:00am
10-K
EX-10.33
0xuwef
1 Mar 21
Annual report
12:00am
10-K
4gfi7ijcbxv
1 Mar 21
Annual report
12:00am
10-K
EX-10.32
i5buu ens9405m
1 Mar 21
Annual report
12:00am
10-K
EX-10.22
uyezy57g
1 Mar 21
Annual report
12:00am
8-K
EX-99.1
9bdkdp7539wco1dc0z4
11 Jan 21
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning
6:52am
8-K
EX-99.1
ghgdcwsq
6 Jan 21
Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China
4:08pm
6-K
EX-99.1
iaehy 0bq1tlr7
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
6-K
EX-99.1
5s61nryp8 sf7qsflg
28 Dec 20
Zai Lab and Cullinan Oncology Announce Strategic
7:30am
6-K
0hn1d5y n2om
9 Oct 20
Current report (foreign)
9:06am
6-K
EX-99.1
hxjo 8y15cwh1
28 Sep 20
Zai Lab Announces Closing of Hong Kong Secondary Listing
7:52am
424B5
91va48noyrcoee47o
23 Sep 20
Prospectus supplement for primary offering
8:06am
6-K
EX-99.1
sf2ge6z17r31ve5bh
22 Sep 20
Zai Lab Announces Pricing of Hong Kong Secondary Listing
8:08am
6-K
EX-1.1
8oiqnd7
21 Sep 20
Current report (foreign)
4:15pm
424B5
tcx792dy
16 Sep 20
Prospectus supplement for primary offering
7:24am
6-K
EX-99.1
qdexngpqeojeh
16 Sep 20
Zai Lab Launches Hong Kong Secondary Listing
7:18am
6-K
EX-99.1
5tk246 r2h9acu5y
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am